WT1 HLA class II-binding peptides and compositions and methods comprising same

• US 8,765,687 B2
• Filed: 10/17/2006
• Issued: 07/01/2014
• Est. Priority Date: 10/17/2005
• Status: Active Grant

• Current Assignee: Memorial Hospital For Cancer & Allied Diseases Incorporated
• Original Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Inventors: Scheinberg, David A., Pinilla-Ibarz, Javier, May, Rena
• Primary Examiner(s): Gupta, Anish
• Application Number:
  US12/083,731
• Publication Number:
  US 20100111986A1
• Time in Patent Office: 2,814 Days
• Field of Search: None
• US Class Current: 514/21.4
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/001153 Wilms tumor 1 [WT1]
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/464453 Wilms tumor 1 [WT1]
• CPC Class Codes: A61K 39/464499 Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

Claims

1. An isolated WT1 peptide consisting of the amino acid sequence

2. The isolated WT1 peptide of claim 1, wherein said isolated WT1 peptide binds to an HLA class II molecule.

3. The isolated WT1 peptide of claim 2, wherein said HLA class II molecule is an HLA-DRB molecule.

4. The isolated WT1 peptide of claim 3, wherein said isolated WT1 peptide binds to a second HLA-DRB molecule, wherein said HLA-DRB molecule of claim 3 and said second HLA-DRB molecule are encoded by separate HLA-DRB alleles.

5. A composition comprising the isolated WT1 peptide of claim 2 and an additional isolated WT1 peptide selected from among SEQ ID NO:

1-4, wherein said additional isolated WT1 peptide binds to an additional HLA class II molecule.

6. A composition comprising the isolated WT1 peptide of claim 4 and an additional isolated WT1 peptide selected from among SEQ ID NO:

1-4, wherein said additional HLA class II molecule is a third HLA-DRB molecule that is different from said HLA-DRB molecule of claim 3 or said second HLA-DRB molecule of claim 4.

7. The composition of claim 6, wherein said additional isolated WT1 peptide binds to a fourth HLA-DRB molecule, wherein said third HLA-DRB molecule of claim 6 and said fourth HLA-DRB molecule are encoded by separate HLA-DRB alleles.

8. A composition comprising the isolated WT1 peptide of claim 1 and an HLA class I molecule-binding WT1 peptide selected from among SEQ ID NO:

5-38.

9. The composition of claim 8, wherein said HLA class I molecule is an HLA-A molecule.

10. The composition of claim 8, wherein the amino acid sequence of said HLA class I molecule-binding WT1 peptide comprises a sequence selected from SEQ ID No:

5-38.

11. A composition comprising (a) the isolated WT1 peptide of claim 1 and (b) an adjuvant or a carrier.

12. The composition of claim 11, wherein said adjuvant is QS21, Freund'"'"'s incomplete adjuvant, aluminum phosphate, aluminum hydroxide, BCG, alum, a growth factor, a cytokine, a chemokine, an interleukin, Montanide ISA 51, or GM-CSF.

13. The composition of claim 5, wherein the isolated WT1 peptide has an amino acid sequence

14. A composition comprising (a) an antigen-presenting cell and (b) a peptide selected from

15. The composition of claim 14, further comprising an additional HLA class II molecule-binding peptide selected from among SEQ ID NO:

1-4, or an HLA class I molecule-binding WT1 peptide selected from among SEQ ID NO;

5-38.

16. The composition of claim 15, wherein said HLA class I molecule is an HLA-A molecule.

17. The composition of claim 15, wherein the amino acid sequence of said HLA class I molecule-binding WT1 peptide comprises a sequence selected from SEQ ID No:

5-38.

18. The composition of claim 14, wherein said antigen-presenting cell presents said peptide on an HLA class II molecule thereof.

19. A composition comprising (a) the composition of claim 14 and (b) an adjuvant or a carrier.

20. The composition of claim 19, wherein said adjuvant is QS21, Freund'"'"'s incomplete adjuvant, aluminum phosphate, aluminum hydroxide, BCG, alum, a growth factor, a cytokine, a chemokine, an interleukin, Montanide ISA 51, or GM-CSF.